Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences (Nasdaq:IDYA) has submitted an Investigational New Drug (IND) application to the FDA for IDE397, a MAT2A inhibitor aimed at treating solid tumors with MTAP deletion. This marks a significant milestone in IDEAYA's research pipeline focused on synthetic lethality therapies. Approximately 15% of solid tumors have the MTAP deletion, representing a potential patient population for IDE397. IDEAYA will share further details at the 39th Annual J.P. Morgan Healthcare Conference, including preclinical data showing tumor regressions and proposed clinical plans.

IDEAYA Biosciences (Nasdaq:IDYA) announced the First-Patient-In (FPI) in a Phase 1 combination study of IDE196 and crizotinib for metastatic uveal melanoma (MUM). This collaboration with Pfizer aims to evaluate the effectiveness of IDE196 alongside the cMET inhibitor crizotinib. IDEAYA's translational research identified cMET as a potential combination agent. The company plans to present preclinical data supporting the IDE196/crizotinib therapy in H1 2021, addressing a significant unmet medical need in treating MUM.

IDEAYA Biosciences (Nasdaq:IDYA) announced participation in key investor and scientific events in January 2021. Events include the JP Morgan 39th Annual Healthcare Conference on January 13 and the HC Wainwright Bioconnect on January 14, both virtual presentations. Additionally, IDEAYA will present at the PARP & DDR Inhibitors Summit on January 28, focusing on innovative cancer treatments. Webcasts will be available on their website, with replays accessible for 30 days. IDEAYA specializes in precision oncology, targeting therapies based on molecular diagnostics.

IDEAYA Biosciences (NASDAQ: IDYA), an oncology-focused precision medicine company, announced its selection for inclusion in the NASDAQ Biotechnology Index, effective prior to market open on December 21, 2020. This index tracks biotechnology and pharmaceutical securities on the NASDAQ and is recognized for its stringent criteria, including market value and share volume requirements. The inclusion may enhance IDEAYA's visibility and credibility in the market, potentially benefiting its stock performance.

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) reported its Q3 2020 financial results, highlighting a cash position of $288.8 million, up from $100.5 million at the end of 2019. With collaboration revenue of $9.0 million, the company advances its synthetic lethality pipeline, including partnerships with GSK. Key updates include the IDE397 program targeting MAT2A, ongoing clinical trials for IDE196 in metastatic uveal melanoma, and strategic collaborations with Broad Institute and UCSD. The net loss for Q3 2020 was $4.9 million, significantly reduced from $11.0 million a year prior.

IDEAYA Biosciences (Nasdaq:IDYA), a precision medicine company focused on oncology, announced its participation in upcoming investor events. The company will present at the Stifel 2020 Healthcare Conference on November 16, 2020, at 1:00 pm PT, and hold a fireside chat at the Jefferies London Healthcare Conference on November 18, 2020, at 9:35 am PT. Live webcasts and subsequent replays will be available on IDEAYA's investor calendar page.

IDEAYA aims to develop targeted therapeutics using molecular diagnostics and biomarkers.

IDEAYA Biosciences (NASDAQ: IDYA) announced a strategic partnership with the Sellers Laboratory at the Broad Institute, focusing on target and biomarker discovery in oncology. Utilizing CRISPR technology, the collaboration aims to explore synthetic lethality in ovarian and breast cancer. IDEAYA's DECIPHER Dual CRISPR platform, developed with UC San Diego, is also highlighted, emphasizing ongoing evaluations of approximately 50,000 gene knockout combinations. The PARG program seeks a development candidate nomination in 2021, with a commitment to building a pipeline of first-in-class cancer therapeutics.

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine company focusing on oncology, announced its participation in several investor relations events in September 2020. Key events include:

• JP Morgan CEO Series on September 8
• Citi 15th Annual BioPharma Conference on September 9
• RW Baird Global Health Care Conference on September 10
• H.C. Wainwright 22nd Annual Global Investment Conference on September 14
• Cantor Fitzgerald Global Healthcare Conference on September 17

Live webcasts of the events will be available on their website.

IDEAYA Biosciences, Inc. (IDYA) reported a transformative Q2 2020, with cash reserves of $172 million and an additional $127.5 million in gross proceeds to fund operations into 2024. The strategic partnership with GSK offers up to $3 billion in milestone opportunities across pipeline programs. Key developments include the nomination of IDE397 for MAT2A and progress on IDE196 in clinical trials. R&D expenses decreased slightly to $8.6 million, while G&A expenses increased to $4 million, contributing to a net loss of $12.4 million.